Syros Pharmaceuticals Inc (NASDAQ:SYRS) shares hit a new 52-week low during trading on Tuesday . The stock traded as low as $9.73 and last traded at $10.40, with a volume of 82,710 shares. The stock had previously closed at $11.29.

Several research analysts recently commented on SYRS shares. HC Wainwright started coverage on Syros Pharmaceuticals in a research report on Monday, July 18th. They issued a “neutral” rating and a $10.00 target price for the company. Piper Jaffray Cos. started coverage on Syros Pharmaceuticals in a research report on Monday, July 25th. They issued an “overweight” rating and a $20.00 target price for the company. Cowen and Company started coverage on Syros Pharmaceuticals in a research report on Monday, July 25th. They issued an “outperform” rating for the company. JMP Securities started coverage on Syros Pharmaceuticals in a research report on Monday, July 25th. They issued an “outperform” rating and a $22.00 target price for the company. Finally, Wedbush started coverage on Syros Pharmaceuticals in a report on Monday, July 25th. They issued an “outperform” rating and a $18.00 price target for the company. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. Syros Pharmaceuticals has an average rating of “Buy” and an average target price of $17.50.

The stock’s market capitalization is $100.26 million. The company has a 50 day moving average price of $0.00 and a 200 day moving average price of $0.00.

In other Syros Pharmaceuticals news, major shareholder Redmile Group, Llc acquired 432,746 shares of the company’s stock in a transaction that occurred on Wednesday, July 6th. The stock was acquired at an average cost of $12.50 per share, for a total transaction of $5,409,325.00. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Robert Nelsen acquired 400,000 shares of the company’s stock in a transaction that occurred on Wednesday, July 6th. The shares were acquired at an average price of $12.50 per share, with a total value of $5,000,000.00. The disclosure for this purchase can be found here.

Syros Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on developing treatments for cancer and immune-mediated diseases. The Company’s gene control platform focuses on identifying gene control targets linked to genomically defined patient populations, and drugging gene control targets.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.